BLTE Belite Bio, Inc.
$173.79
Belite Bio, Inc. (BLTE) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Insider signal
In line
Selling ran in line with BLTE's own trailing one-year pace, with 93% of sale value under a prearranged plan.
Cluster activity
0 buyers in the last 30 days
0 buyers in the last 90 days
3 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
5
167 transactions
Purchases
$0
0 shares
Sales
$40.5M
221,728 shares
Net activity
-$40.5M
purchases less sales
How much of that selling was preplanned? 93% planned / 7% discretionary
10b5-1 plan sales
$37.7M
154 transactions · 201,728 shares
Discretionary sales
$2.9M
13 transactions · 20,000 shares
Largest single sale: $2.1M.
Where they traded
Buy
Sell
Dot area is proportional to transaction value.
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Lin Yu-Hsin 5 fills | Chief Executive Officer | Sell 10b5-1 | 26,000 | $196.56 | $5.1M | 93,734 −21.7% of holding | |
| Chuang Hao-Yuan 5 fills | Chief Financial Officer | Sell 10b5-1 | 17,962 | $196.42 | $3.5M | 41,800 −30.1% of holding | |
| Lin Yu-Hsin 14 fills | Chief Executive Officer | Sell 10b5-1 | 74,435 | $187.71 | $14.0M | 167,934 −30.7% of holding | |
| Chuang Hao-Yuan 14 fills | Chief Financial Officer | Sell 10b5-1 | 49,433 | $187.64 | $9.3M | 91,800 −35% of holding | |
| Chuang Hao-Yuan 2 fills | Chief Financial Officer | Sell 10b5-1 | 367 | $180.35 | $66.2K | 93,656 −0.4% of holding | |
| Lin Yu-Hsin 2 fills | Chief Executive Officer | Sell 10b5-1 | 365 | $180.35 | $65.8K | 170,792 −0.2% of holding | |
| Scholl Hendrik Peter 5 fills | Chief Medical Officer | Sell | 10,000 | $145.24 | $1.5M | 24,904 −28.7% of holding | |
| Scholl Hendrik Peter 8 fills | Chief Medical Officer | Sell | 10,000 | $140.57 | $1.4M | 32,946 −23.3% of holding | |
| MATA NATHAN L. 4 fills | Chief Scientific Officer | Sell 10b5-1 | 666 | $153.21 | $102.0K | 440 −60.2% of holding | |
| MATA NATHAN L. 6 fills | Chief Scientific Officer | Sell 10b5-1 | 1,000 | $153.84 | $153.8K | 1,658 −37.6% of holding | |
| MATA NATHAN L. 6 fills | Chief Scientific Officer | Sell 10b5-1 | 1,000 | $155.50 | $155.5K | 2,546 −28.2% of holding | |
| MATA NATHAN L. 5 fills | Chief Scientific Officer | Sell 10b5-1 | 1,000 | $155.64 | $155.6K | 3,634 −21.6% of holding | |
| MATA NATHAN L. 8 fills | Chief Scientific Officer | Sell 10b5-1 | 1,000 | $155.78 | $155.8K | 4,614 −17.8% of holding | |
| MATA NATHAN L. 4 fills | Chief Scientific Officer | Sell 10b5-1 | 1,000 | $156.97 | $157.0K | 5,624 −15.1% of holding | |
| MATA NATHAN L. 5 fills | Chief Scientific Officer | Sell 10b5-1 | 1,000 | $155.82 | $155.8K | 6,388 −13.5% of holding | |
| MATA NATHAN L. 9 fills | Chief Scientific Officer | Sell 10b5-1 | 1,000 | $159.16 | $159.2K | 7,654 −11.6% of holding | |
| MATA NATHAN L. 5 fills | Chief Scientific Officer | Sell 10b5-1 | 1,000 | $162.64 | $162.6K | 8,622 −10.4% of holding | |
| MATA NATHAN L. 6 fills | Chief Scientific Officer | Sell 10b5-1 | 1,000 | $159.56 | $159.6K | 9,592 −9.4% of holding | |
| MATA NATHAN L. 6 fills | Chief Scientific Officer | Sell 10b5-1 | 1,000 | $166.28 | $166.3K | 10,399 −8.8% of holding | |
| MATA NATHAN L. 9 fills | Chief Scientific Officer | Sell 10b5-1 | 1,000 | $170.38 | $170.4K | 11,635 −7.9% of holding | |
| MATA NATHAN L. 5 fills | Chief Scientific Officer | Sell 10b5-1 | 1,000 | $166.00 | $166.0K | 12,602 −7.4% of holding | |
| MATA NATHAN L. 7 fills | Chief Scientific Officer | Sell 10b5-1 | 1,000 | $163.59 | $163.6K | 13,382 −7% of holding | |
| MATA NATHAN L. 6 fills | Chief Scientific Officer | Sell 10b5-1 | 1,000 | $161.63 | $161.6K | 14,634 −6.4% of holding | |
| MATA NATHAN L. 7 fills | Chief Scientific Officer | Sell 10b5-1 | 1,000 | $160.38 | $160.4K | 15,450 −6.1% of holding | |
| MATA NATHAN L. 5 fills | Chief Scientific Officer | Sell 10b5-1 | 1,000 | $168.30 | $168.3K | 16,283 −5.8% of holding | |
| Lin Yu-Hsin 4 fills | Chief Executive Officer | Sell 10b5-1 | 9,200 | $181.45 | $1.7M | 177,634 −4.9% of holding | |
| Chuang Hao-Yuan 4 fills | Chief Financial Officer | Sell 10b5-1 | 6,200 | $181.50 | $1.1M | 98,000 −6% of holding | |
| Chen Wan-Shan | Director | Sell 10b5-1 | 1,100 | $180.43 | $198.5K | 9,096 −10.8% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.